Amendments to the Claims

Please amend claims 1 and 13, as shown below.

Please cancel claims 11 and 12 without prejudice.

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1. (Currently amended) A therapeutic composition for the elicitation of a systemic, non-antigen specific immune response in a mammal comprising:

a. a liposome delivery vehicle; and

b. ~~an oligonucleotide~~ a DNA molecule containing no CpG motifs and from more than [[10]] 25 to about [[500]] 100 nucleotides in length;

wherein said therapeutic composition elicits a ~~systemic, non-antigen-specific~~ Th1 immune response in said mammal.

2. (Original) The composition of claim 1, wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

3. (Original) The composition of claim 1, wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.

4. (Original) The composition of claim 1, wherein said liposome delivery vehicle comprises cationic liposomes.

5. (Original) The composition of claim 1, wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol;

DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.

6. (Original) The composition of claim 1, wherein said liposome delivery vehicle comprises DOTAP and cholesterol.

7. (Original) The composition of claim 1, further comprising a pharmaceutically acceptable excipient.

8. (Original) The composition of claim 7, wherein said excipient comprises a non-ionic diluent.

9. (Original) The composition of claim 7, wherein said excipient is 5 percent dextrose in water.

10. (Original) The composition of claim 1, wherein said composition has a nucleic acid to lipid ratio of from about 1:1 to about 1:64.

11-12 (Canceled)

13 (Currently amended) A method for eliciting a ~~systemic, non-antigen specific~~ Th1 immune response in a mammal, said method comprising administering to said mammal an amount of a composition effective to elicit said Th1 immune response, wherein said composition comprises:

a. a liposome delivery vehicle; and

b. ~~an oligonucleotide~~ a DNA molecule containing no CpG motifs and from more than [[10]] 25 to about [[500]] 100 nucleotides in length.

14. (Original) The method of claim 13, wherein said liposome delivery vehicle

comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

15. (Previously presented) The method of claim 13, wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.

16. (Original) The method of claim 13, wherein said liposome delivery vehicle comprises cationic liposomes.

17. (Original) The method of claim 13, wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol; DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.

18. (Original) The method of claim 13, wherein said liposome delivery vehicle comprises DOTAP and cholesterol.

19. (Original) The method of claim 13, wherein said composition further comprises a pharmaceutically acceptable excipient.

20. (Original) The method of claim 19, wherein said excipient comprises a non-ionic diluent.

21. (Original) The method of claim 21, wherein said excipient is 5 percent dextrose in water.

22. (Original) The method of claim 13, wherein said composition has a nucleic acid to lipid ratio of from about 1:1 to about 1:64.